Kiromic Biopharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Kiromic Biopharma's Q3 2024 report reveals ongoing losses and a going concern warning, despite clinical trial progress with Deltacel.
Kiromic Biopharma's Q2 2024 results reveal ongoing losses and a precarious financial position, raising substantial doubt about the company's ability to continue as a going concern.
Kiromic BioPharma's Q1 2024 results show a net loss of $6.1 million and raise substantial doubt about the company's ability to continue as a going concern due to insufficient cash.